Last reviewed · How we verify
NCT06673290
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
Phase 2, PHASE3 trial testing Sirolimus (RAPAMUNE) in Lymphatic Malformation in 150 participants. Currently enrolling.
30 December 2026
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 30 November 2024 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sirolimus (RAPAMUNE)
Conditions studied
- Lymphatic Malformation — all drugs for Lymphatic Malformation →
Sponsor
West China Hospital
Who can join
Adults 1 to 18, any sex, with Lymphatic Malformation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of cystic lymphatic malformation.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
PI3K/AKT/mTOR axis in vascular malformations: from molecular insights to targeted clinical trials.
Zheng YY, Hua C, Lin XX. · · 2025 · cited 1× · PMID 41430313 · DOI 10.1186/s13023-025-04115-2 -
Vascular malformations: from genetics to therapeutics.
Morin G, Galasso I, Canaud G. · · 2026 · PMID 41272322 · DOI 10.1038/s44321-025-00344-x
Verify or expand the search:
- PubMed search for NCT06673290
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphatic Malformation
Currently open trials in the same condition.
- NCT06892964 — Institution of an Italian Registry and Biobank for Biological Sample Collection · NA · recruiting
- NCT06437158 — Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients · Phase 2 · recruiting
- NCT06275022 — A Prospective Study on the Treatment of cLM Based on ICG Imaging · NA · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06673290 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 31 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06673290.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing